**Jaguar Health, Inc. Navigates Financial Landscape with Strategic Realignment and Pipeline Development**
Jaguar Health, Inc., along with its subsidiary Napo Pharmaceuticals, is focused on developing plant-derived prescription drugs for gastrointestinal diseases. The company reported net revenues of $11.51 million for the year ended December 31, 2025, a slight decrease of 1.5% compared to $11.69 million in 2024. This revenue includes $11.34 million in net product revenue and $172,000 in license revenue. The company's net loss for 2025 was $54.0 million, compared to a net loss of $39.3 million in 2024.
A significant strategic shift occurred in January 2026 when Jaguar Health licensed its U.S. rights for Mytesi and Canalevia-CA1 to Future Pak, generating $16 million in non-dilutive capital. This agreement also includes potential milestone payments of up to $20 million based on future net sales. Jaguar Health will continue to manufacture crofelemer for both products. The company is also focusing on the development of crofelemer powder for oral solution for rare disease indications, including microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF).
Operationally, Jaguar Health is advancing its pipeline with ongoing clinical trials for crofelemer powder for oral solution in MVID and SBS-IF. The company is also planning to submit the final clinical study report for the OnTarget trial to the FDA, along with additional details of the responder analysis in breast cancer patients. In April 2024, Jaguar Health signed an exclusive in-license agreement with Venture Life Group PLC for Gelclair, an oral mucositis prescription product, which was commercially launched in the U.S. in October 2024. As of December 31, 2025, the company had 47 employees, with a focus on research and development and sales and marketing activities.
Looking ahead, Jaguar Health faces the challenge of securing additional capital to fund its operations and clinical trials. The company's management acknowledges substantial doubt about its ability to continue as a going concern without additional funding. The company plans to pursue partnerships for the development and commercialization of crofelemer powder for oral solution and NP-300, a second-generation anti-secretory antidiarrheal drug. The company is also seeking regulatory designations such as PRIME and Breakthrough Therapy Designation to expedite the review and approval process for its pipeline products.
About Jaguar Health, Inc.
Jaguar Health, Inc. develops plant-derived prescription medicines targeting gastrointestinal disorders in humans and animals. Its core products include crofelemer-based drugs like Mytesi for HIV-related diarrhea and Canalevia for canine diarrhea. The company focuses on unmet medical needs such as cancer therapy-related diarrhea, rare diseases, and supportive care, leveraging sustainable botanical sources and proprietary formulations to provide first-in-class, natural treatment options globally.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.